STAT3 and diffuse large B-cell lymphoma: Constitutively activated Stat3 in ABC-DLBCL is associated with poor survival [15]; moreover, Stat3 activation is a biomarker for poor survival in DLBCL after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treatment [16].